Immupharma PLC
06 August 2007
For Immediate Release 6 August 2007
Grant of Options
ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug
discovery and development company, announces the granting of share options to
its Directors. The Company has adopted a HM Revenue & Customs approved share
ownership plan (CSOP) and an unapproved share option scheme.
The amount of options granted are summarised in the following table:
Director Options Granted
Richard Warr 140,000
Robert Zimmer 150,000
Dimitri Dimitriou 140,000
Franco di Muzio 100,000
Ajay Agrawal 100,000
The option price was set at 76.8p per share. The options are exercisable after 3
years and up to 10 years from being granted.
For further information, please contact:
ImmuPharma PLC
Dimitri Dimitriou, Chief Executive Officer + 44 020 7152 4080
Richard Warr, Chairman
Dr Robert Zimmer, President & Chief Scientific Officer +33 389 32 76 50
Buchanan Communications +44 20 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich
Teather & Greenwood (NOMAD & Broker) +44 020 7426 9000
Thilo Hoffmann
Jeff Keating
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.